C07K 7/067
Hemoregulatory peptides based on sequence glp-glu-asp-cys-lys
Official title: {Hemoregulatory peptides based on sequence Glp-Glu-Asp-Cys-Lys}
C07K7/067 (Hemoregulatory peptides based on sequence glp-glu-asp-cys-lys) appears on 18 US grants and 6 published applications in this corpus.
Search patents in C07K- Granted patents
- 18
- Published applications
- 6
- Assignees
- 9
- Inventors
- 24
- Latest grant
- 15 Feb 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 4 | 0 |
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 1 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 1 | 1 |
| 2016 | 0 | 0 |
| 2017 | 1 | 2 |
| 2018 | 0 | 0 |
| 2019 | 1 | 0 |
| 2020 | 0 | 1 |
| 2021 | 0 | 0 |
| 2022 | 1 | 0 |
By publication year. Applications have been published since 2001.
Recent patents
- Suspension formulation comprising an insulinotropic peptide15 Feb 2022US 11,246,913 B2Intarcia Therapeutics, Inc.
- Method of manufacturing an osmotic delivery device30 Jul 2019US 10,363,287 B2Intarcia Therapeutics, Inc.
- Osmotic delivery device comprising an insulinotropic peptide and uses thereof20 Jun 2017US 9,682,127 B2Intarcia Therapeutics, Inc.
- Osmotic delivery comprising an insulinotropic peptide and uses thereof27 Jan 2015US 8,940,316 B2Intarcia Therapeutics, Inc.
- Suspension formulations of insulinotropic peptides and uses thereof30 Oct 2012US 8,299,025 B2Intarcia Therapeutics, Inc.
- Method of manufacturing an osmotic delivery device20 Feb 2020US 2020/0054717 A1Intarcia Therapeutics, Inc.
- Osmotic delivery device comprising an insulinotropic peptide and uses thereof28 Dec 2017US 2017/0368145 A1Intarcia Therapeutics, Inc.
- Osmotic delivery device comprising an insulinotropic peptide and uses thereof16 Mar 2017US 2017/0072022 A1Intarcia Therapeutics, Inc.
- Osmotic delivery device comprising an insulinotropic peptide and uses thereof17 Sep 2015US 2015/0258016 A1Intarcia Therapeutics, Inc.
- Suspension formulations of insulinotropic peptides and uses thereof12 Jul 2012US 2012/0178687 A1Intarcia Therapeutics, Inc.
Most cited
By later US patents
- Suspension formulations of insulinotropic peptides and uses thereof54US 8,299,025 B2Intarcia Therapeutics, Inc. · 2012
- Osmotic delivery comprising an insulinotropic peptide and uses thereof26US 8,940,316 B2Intarcia Therapeutics, Inc. · 2015
- Osmotic delivery device comprising an insulinotropic peptide and uses thereof21US 9,682,127 B2Intarcia Therapeutics, Inc. · 2017
- Peptide compounds12US 4,499,081 ANyegaard & Co. A.S. · 1985
- Double chain peptide compounds having hemoregulatory activity4US 5,610,141 ANycomed Imaging AS · 1997